Tony became CEO of NeoGenomics in April 2025. Prior to becoming CEO, he was a Board member for two years, serving as Chair of the Compensation committee and a member of the Audit and Technology committees. Tony has significant experience as a brand and marketing executive, with a focus on managing the interface between commercial and research and development aspects of an organization.

With 40 years of executive leadership in medical device and health care services, David serves as an independent board member and advisor to several corporations and nonprofit organizations. His expertise encompasses growing and scaling highly regulated global businesses organically through R&D and innovation and inorganically through M&A, leading within a variety of foreign, public, and private equity ownership structures; strategic planning; culture and talent development; succession planning; enterprise risk management; operations; compliance; and corporate governance.

As CIO, Andrew will lead our new Office of Innovation, driving cutting-edge research and development while ensuring continuous advancement and integration of new technologies. He will also oversee our Quality, Regulatory, and Clinical Studies teams.     

Ali has been serving as General Counsel since mid-April 2022. She has more than 14 years of corporate and legal expertise. She has been with NeoGenomics for over 5 years, representing the company in its acquisition of Inivata and Trapelo Health, as well as fundraising and governance activities. At NeoGenomics, she has also represented the company in various regulatory matters, including before the College of American Pathologists (CAP), the Office for Civil Rights (OCR), and the Office of Inspector General (OIG).